DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine
Authors:
- 2 November 2022
- journal article
- review article
- Published by Springer Nature in EPMA Journal
- Vol. 13 (4) , 649-669
Abstract
Lung cancer has a very high mortality in females and males. Most (~ 85%) of lung cancers are non-small cell lung cancers (NSCLC). When lung cancer is diagnosed, most of them have either local or distant metastasis, with a poor prognosis. In order to achieve better outcomes, it is imperative to identify the molecular signature based on genetic and epigenetic variations for different NSCLC subgroups. We hypothesize that DNA and histone modifications play significant roles in the framework of predictive, preventive, and personalized medicine (PPPM; 3P medicine). Epigenetics has a significant impact on tumorigenicity, tumor heterogeneity, and tumor resistance to chemotherapy, targeted therapy, and immunotherapy. An increasing interest is that epigenomic regulation is recognized as a potential treatment option for NSCLC. Most attention has been paid to the epigenetic alteration patterns of DNA and histones. This article aims to review the roles DNA and histone modifications play in tumorigenesis, early detection and diagnosis, and advancements and therapies of NSCLC, and also explore the connection between DNA and histone modifications and PPPM, which may provide an important contribution to improve the prognosis of NSCLC. We found that the success of targeting DNA and histone modifications is limited in the clinic, and how to combine the therapies to improve patient outcomes is necessary in further studies, especially for predictive diagnostics, targeted prevention, and personalization of medical services in the 3P medicine approach. It is concluded that DNA and histone modifications are potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine.Keywords
Funding Information
- the Shandong First Medical University Talent Introduction Funds
- Shandong First Medical University High-level Scientific Research Achievement Cultivation Funding Program
- the Shandong Provincial Natural Science Foundation
This publication has 172 references indexed in Scilit:
- Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell ProliferationJournal of Biological Chemistry, 2012
- Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG IslandsCancer Cell, 2011
- Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progressionProceedings of the National Academy of Sciences, 2011
- The diverse functions of Dot1 and H3K79 methylationGenes & Development, 2011
- Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joiningNature Structural & Molecular Biology, 2010
- Efficient Formation of the Tandem Thymine Glycol/8-Oxo-7,8-dihydroguanine Lesion in Isolated DNA and the Mutagenic and Cytotoxic Properties of the Tandem Lesions in Escherichia coli CellsChemical Research in Toxicology, 2009
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid TumorsClinical Cancer Research, 2009
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1Science, 2009
- High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancerProceedings of the National Academy of Sciences, 2008
- Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsGenes & Development, 2007